Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1975 May;55(5):1111–1118. doi: 10.1172/JCI108012

Immunochemical heterogeneity of calcitonin in plasma of patients with medullary thryoid carcinoma.

G W Sizemore, H Hpeath 3rd, J M Larson
PMCID: PMC301858  PMID: 47335

Abstract

Marked discrepancies (values up to four times higher in on assay than in the other) were observed when the plasma concentration of immunoreactive human calcitonin (iCT) was measured by two radioimm8noassays in 18 patients with medullary thyroid carcinoma. The two antisera used had different binding affinities for the NH2- and COOH-terminal regions of synthetic calcitonin monomer (CT-1-32). Except for this difference, the assays were identical and reacted equally with CT 1-32. Plasma samples from patients with medullary thyroid carcinoma were gel filtered on columns of Bio-Gel P-150, and the immunoreactivity in column effuent fractions was measured with both assays. The one utilizing the antiserum with prominent NH2-terminal binding affinity (and giving higher iCT values) recognized at least five molecular species that eluted with or before CT 1-32. The other assay, utilizing the antiserum with a COOH-terminal binding affinity, recognized two fo these molecular species-one eluting with CT 1-32 and the other in a position consistent with a dimer. A mixture of athreotic asthma and added CT 1-32 contained a single immunologic species that was recoqnized equally by both antisera. No forms smaller than CT 1-32 were detected in any study. The results suggest that iCT circulating in the plasma of patients with medullary thryoid carcinoma is hetergeneous. The absolute iCT concentration measured by radioimmunoassays depends on recognition of these distinct molecular species as well as on the specific binding affinities of the antiserum used to detect them. These observations may partially explain the variations among iCT values reported by different laboratories.

Full text

PDF
1111

Images in this article

1114Image
on p.1114
1114Image
on p.1114
1114Image
on p.1114

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnaud C. D., Goldsmith R. S., Bordier P. J., Sizemore G. W. Influence of immunoheterogeneity of circulating parathyroid hormone on results of radioimmunoassays of serum in man. Am J Med. 1974 Jun;56(6):785–793. doi: 10.1016/0002-9343(74)90806-7. [DOI] [PubMed] [Google Scholar]
  2. Arnaud C. D., Tsao H. S., Littledike T. Radioimmunoassay of human parathyroid hormone in serum. J Clin Invest. 1971 Jan;50(1):21–34. doi: 10.1172/JCI106476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Benson R. C., Jr, Riggs B. L., Pickard B. M., Arnaud C. D. Immunoreactive forms of circulating parathyroid hormone in primary and ectopic hyperparathyroidism. J Clin Invest. 1974 Jul;54(1):175–181. doi: 10.1172/JCI107739. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Berson S. A., Yalow R. S. Immunochemical heterogeneity of parathyroid hormone in plasma. J Clin Endocrinol Metab. 1968 Jul;28(7):1037–1047. doi: 10.1210/jcem-28-7-1037. [DOI] [PubMed] [Google Scholar]
  5. Byfield P. G., Clark M. B., Turner K., Foster G. V., MacIntyre I. Immunochemical studies on human calcitonin M leading to information on the shape of the molecule. Biochem J. 1972 Mar;127(1):199–206. doi: 10.1042/bj1270199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Canterbury J. M., Reiss E. Multiple immunoreactive molecular forms of parathyroid hormone in human serum. 1. Proc Soc Exp Biol Med. 1972 Sep;140(4):1393–1398. doi: 10.3181/00379727-140-36681. [DOI] [PubMed] [Google Scholar]
  7. Deftos L. J., Bury A. E., Habener J. F., Singer F. R., Potts J. T., Jr Immunoassay for human calcitonin. II. Clinical studies. Metabolism. 1971 Dec;20(12):1129–1137. doi: 10.1016/0026-0495(71)90038-2. [DOI] [PubMed] [Google Scholar]
  8. Dietrich F. M., Rittel W. Antigenic site(s) of synthetic human calcitonin M. Nature. 1970 Jan 3;225(5227):75–76. doi: 10.1038/225075a0. [DOI] [PubMed] [Google Scholar]
  9. GOODFRIEND T. L., LEVINE L., FASMAN G. D. ANTIBODIES TO BRADYKININ AND ANGIOTENSIN: A USE OF CARBODIIMIDES IN IMMUNOLOGY. Science. 1964 Jun 12;144(3624):1344–1346. doi: 10.1126/science.144.3624.1344. [DOI] [PubMed] [Google Scholar]
  10. Hesch R. D., Woodhead J. S., Hüfner M., Dietrich F. M. Radioimmunometric assay for human calcitonin. Acta Endocrinol Suppl (Copenh) 1973;173:161–161. doi: 10.1530/acta.0.072s161. [DOI] [PubMed] [Google Scholar]
  11. Heynen G., Franchimont P. Human calcitonin radioimmunoassay in normal and pathological conditions. Eur J Clin Invest. 1974 Jun;4(3):213–222. doi: 10.1111/j.1365-2362.1974.tb00395.x. [DOI] [PubMed] [Google Scholar]
  12. Moukhtar M. S., Jullienne A., Tharaud D., Taboulet J., Milhaud G. Extraction et concentration de la calcitonine plasmatique humaine par des anticorps couplés sur support solide. C R Acad Sci Hebd Seances Acad Sci D. 1973 Jun 25;276(26):3445–3448. [PubMed] [Google Scholar]
  13. Neher R., Riniker B., Maier R., Byfield P. G., Gudmundsson T. V., MacIntyre I. Human calcitonin. Nature. 1968 Dec 7;220(5171):984–986. doi: 10.1038/220984a0. [DOI] [PubMed] [Google Scholar]
  14. Riniker B., Neher R., Maier R., Kahnt F. W., Byfield P. G., Gudmundsson T. V., Galante L., MacIntyre I. Menschliches Calcitonin. I. Isolierung und Charakterisierung. Helv Chim Acta. 1968 Oct 31;51(7):1738–1742. doi: 10.1002/hlca.19680510731. [DOI] [PubMed] [Google Scholar]
  15. Segre G. V., Habener J. F., Powell D., Tregear G. W., Potts J. T. Parathyroid Hormone in Human Plasma: IMMUNOCHEMICAL CHARACTERIZATION AND BIOLOGICAL IMPLICATIONS. J Clin Invest. 1972 Dec;51(12):3163–3172. doi: 10.1172/JCI107143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Silva O. L., Snider R. H., Becker K. L. Radioimmunoassay of calcitonin in human plasma. Clin Chem. 1974 Mar;20(3):337–339. [PubMed] [Google Scholar]
  17. Sizemore G. W., Go V. L., Kaplan E. L., Sanzenbacher L. J., Holtermuller K. H., Arnaud C. D. Relations of calcitonin and gastrin in the Zollinger-Ellison syndrome and medullary carcinoma of the thyroid. N Engl J Med. 1973 Mar 29;288(13):641–644. doi: 10.1056/NEJM197303292881301. [DOI] [PubMed] [Google Scholar]
  18. Steiner A. L., Goodman A. D., Powers S. R. Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2. Medicine (Baltimore) 1968 Sep;47(5):371–409. doi: 10.1097/00005792-196809000-00001. [DOI] [PubMed] [Google Scholar]
  19. Tashijan A. H., Jr, Howland B. G., Melvin K. E., Hill C. S., Jr Immunoassay of human calcitonin. N Engl J Med. 1970 Oct 22;283(17):890–895. doi: 10.1056/NEJM197010222831702. [DOI] [PubMed] [Google Scholar]
  20. Tashjian A. H., Jr Immunoassay of thyrocalcitonin. I. The method and its serological specificity. Endocrinology. 1969 Jan;84(1):140–148. doi: 10.1210/endo-84-1-140. [DOI] [PubMed] [Google Scholar]
  21. Voelkel E. F., Tashjian A. H., Jr Measurement of thyrocalcitonin-like activity in urine of patients with medullary carcinoma. J Clin Endocrinol Metab. 1971 Jan;32(1):102–109. doi: 10.1210/jcem-32-1-102. [DOI] [PubMed] [Google Scholar]
  22. WOOLNER L. B., BEAHRS O. H., BLACK B. M., McCONAHEY W. M., KEATING F. R., Jr Classification and prognosis of thyroid carcinoma. A study of 885 cases observed in a thirty year period. Am J Surg. 1961 Sep;102:354–387. doi: 10.1016/0002-9610(61)90527-x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES